Navigation Links
Sequenom, Inc. Reports Financial Results For The Third Quarter Of 2013
Date:11/7/2013

methods with discovery of a natural phenomenon fails to qualify as patent-eligible subject matter in accordance with Section 101 of the patent code.

"We believe the court's decision is wrong and misapplies or ignores controlling law," said Welch. "We believe that Drs. Lo and Wainscoat invented a novel method for detecting paternally inherited fetal DNA in maternal plasma and that their invention is more than just the discovery of a natural phenomenon. We intend to appeal the court's order to the United States Court of Appeals for the Federal Circuit."In August 2013, the United States Court of Appeals for the Federal Circuit, in a 3-0 decision, vacated the District Court's order denying the Company's motion for a preliminary injunction and corrected the District Court's preliminary claim construction. The October 30 summary judgment does not impact the current competitive landscape, as the Company has competed without the benefit of the patent being recognized.

Non-GAAP Financial Measures "GAAP" refers to financial information presented in accordance with generally accepted accounting principles in the United States. To supplement the condensed consolidated financial statements and discussion presented on a GAAP basis, this press release includes non-GAAP financial measures with respect to the quarter and nine months ended September 30, 2013. Management uses non-GAAP financial measures because it believes the appropriate analysis of our performance cannot be effectively considered while incorporating the effect of items and charges that have not been experienced consistently in prior periods. The Company reported the following non-GAAP financial measures: "adjusted net loss" and "adjusted net loss per share." These non-GAAP financial measures are not in accordance with or an alternative to GAAP.

Adjusted net earnings exclude the impact of charges associated with restructuring our operations including the impairment of intangible assets. Adjuste
'/>"/>

SOURCE Sequenom, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Sequenom, Inc. Announces Date Of Third Quarter 2013 Financial Results And Conference Call
2. Todays Research: Inovio Pharma, Sequenom, Peregrine Pharma, Onyx Pharma, and Optimer Pharma
3. Sequenom, Inc. Reports Financial Results For The First Quarter Of 2013
4. Morning Research on Sequenom, Peregrine Pharma, Onyx Pharma, and Inovio Pharma
5. Sequenom, Inc. Reports Financial Results For The Fourth Quarter And Full Year Of 2012
6. Sequenom, Inc. Announces Date Of Fourth Quarter And Full Year 2012 Financial Results And Conference Call
7. Sequenom, Inc. Reports Financial Results For The First Quarter Of 2012
8. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2013 Financial Results
9. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
10. ANI Pharmaceuticals Reports Net Revenues of $7.8 million, adjusted Non-GAAP EBITDA of $1.7 Million, and EPS of $0.13 for the Third Quarter Ended September 30, 2013
11. NxStage Reports Third Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... LONDON , Sept. 16, 2014 ... wound closure market, Frost & Sullivan recognises Incisive ... Award for Customer Value Leadership. Incisive Surgical,s uniquely-designed, ... closure technology that eliminates the need for patients ... punctures and staple removal  that may result in ...
(Date:9/16/2014)... , Sept. 16, 2014 CorMedix Inc. ... on developing and commercializing therapeutic products for the ... diseases, announces the amendment and restatement of its ... stock and related warrants, as well as the ... and warrant financing, to remove anti-dilution, price reset ...
(Date:9/16/2014)...  DNAtrix, Inc., experts in oncolytic virus development, ... with the company,s lead product, DNX-2401, a replication ... multicenter, open-label Phase Ib study for patients with ... leading neurosurgeons and neuro-oncologists in the US, is ... Phase Ib study of DNX-2401 at Moffitt Cancer ...
Breaking Medicine Technology:Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 2Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 3Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 4Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 5CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 2CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 3DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial 2
... ALTO, Calif., Dec. 21, 2010 Jazz Pharmaceuticals, Inc. ... United States Patent and Trademark Office (USPTO) has issued ... titled "Microbiologically Sound and Stable Solutions of Gamma-Hydroxybutyrate Salt ... 7,851,506, is also listed in the FDA,s Approved Drug ...
... Today, Pepex Biomedical, Inc. announced that the company has ... Therapeutic Discovery Project created by Congress as a component ... 2010, the major health care reform bill, signed into ... submitted their ground-breaking, patented, electrochemical biosensor, nanotechnology and the ...
Cached Medicine Technology:Jazz Pharmaceuticals Announces New Patent Issued for Sodium Oxybate 2Pepex™ Awarded Qualifying Therapeutic Discovery Project Grant 2
(Date:9/16/2014)... Dotinga HealthDay Reporter , MONDAY, ... baldness may face a higher risk of developing an aggressive ... new study suggests. But, the study authors noted that ... of baldness should be concerned. Their study only found an ... did not prove cause and effect. "It is conceivable ...
(Date:9/16/2014)... After working together for eight years and ... fertility centers in the late 1990s and early 2000s, Dr. ... hometown of New York City to launch Chelsea Fertility of ... , Chelsea Fertility NYC offers full service fertility treatment ... New York Tri-State Area, and provides equal access to care ...
(Date:9/16/2014)... New Jersey (PRWEB) September 16, 2014 ... Infinity Development Partners of San Antonio, TX. has been ... Army facilities located throughout the US, including Alaska and ... Army’s Energy Initiatives Task Force (EITF) and the Corps ... a $7 Billion MATOC primarily to fund renewable and ...
(Date:9/16/2014)... Alachua, FL (PRWEB) September 16, 2014 ... technology company focused on the peripheral nerve repair market, ... the American Society for Surgery of the Hand (ASSH) ... John B. Hynes Convention Center in Boston, MA. , ... outcomes in surgical nerve repair, featuring a discussion by ...
(Date:9/16/2014)... September 16, 2014 Much of the ... major extended drought crisis that in many regions affects ... the many individuals who are dedicated to solving the ... solutions overlook large portion of the problem. Partial solutions, ... crises.     , Grigg explained his, “total water management” concept ...
Breaking Medicine News(10 mins):Health News:Male Pattern Baldness Tied to Prostate Cancer, Study Suggests 2Health News:Male Pattern Baldness Tied to Prostate Cancer, Study Suggests 3Health News:Chelsea Fertility NYC Offers New and Affordable Fertility Treatment Options for Patients in the New York Tri-State Area 2Health News:Chelsea Fertility NYC Offers New and Affordable Fertility Treatment Options for Patients in the New York Tri-State Area 3Health News:Chelsea Fertility NYC Offers New and Affordable Fertility Treatment Options for Patients in the New York Tri-State Area 4Health News:Solar Construction Opportunity at U.S Army Installations Awarded to Pfister Energy & Infinity Development 2Health News:AxoGen, Inc. to Host Surgeon Education Event at American Society for Surgery of the Hand 2014 Annual Meeting 2Health News:AxoGen, Inc. to Host Surgeon Education Event at American Society for Surgery of the Hand 2014 Annual Meeting 3Health News:Drought Solutions Overlook Too Many Factors Water Policy Expert Warns Sharon Kleyne 2Health News:Drought Solutions Overlook Too Many Factors Water Policy Expert Warns Sharon Kleyne 3
... men after bypass surgery, according to a new study done ... say whether the //results are due to medical or psychosocial ... outcomes after bypass surgery than men. Most have attributed this ... generally older, sicker, and have fewer social supports. In this ...
... is when symptoms have lasted for less than three ... self-management program that includes group classes, exercise sheet handouts, ... manage their back pain. ,Researchers from Indiana University ... low back pain. The program focuses on boosting confidence ...
... study shows hydrotherapy, or water exercise, may improve strength and ... studied more than 100 patients with osteoarthritis who were older ... first group exercised three times a week in a swimming ... did not exercise at all. Both the water and gym ...
... may improve strength and mobility in patients with osteoarthritis.// ... who were older than age 50. Patients were divided into ... in a swimming pool, the second exercised in a gym, ... water and gym programs focused on resistance exercises. ,Results ...
... lasted for less than three months. ,A new study ... sheet// handouts, and telephone follow-up calls may help patients ... from Indiana University developed a self-management program for poor, ... on boosting confidence in order to increase their motivation ...
... reducing the signs of aging in the neck. The procedure involves ... reduce the saggy appearance of the neck. Researchers say this new ... are often changes in the neck and face including the loss ... of fat in the neck. This causes the skin to sag. ...
Cached Medicine News:
Inquire...
... Roches patented polymerase chain reaction (PCR) ... technology, is an essential component of Roches ... PCR allows minute amounts of selected unique ... into billions of copies (that is, to ...
... Introducing BenchMark XT® the only fully ... flexibility you need to expand your ... improve your slide turnaround time. All ... choose how to use the BenchMark ...
... Reicherts new ATP Auto Non-Contact Tonometer / ... / pachymeter, combining the measurement of IOP ... response to numerous clinical studies that have ... thickness as well as intraocular pressure in ...
Medicine Products: